Cambridge Healthtech Institute’s Inaugural
Emerging T Cell Engagers
Next-Gen TCEs with Improved Safety and Efficacy
May 11-12, 2026
Cambridge Healthtech Institutes’s inaugural Emerging T Cell Engagers conference showcases the next wave of T cell engagers (TCEs) and immune engagers for cancer, autoimmune, and infectious disease. Sessions will highlight engineering innovations to improve TCE safety, efficacy, and tumor selectivity in hematologic malignancies and solid tumors—including affinity tuning, AI-guided target discovery and drug design, conditional activation, and targeting. Experts will discuss strategies to optimize synapse formation and enhance delivery, while sessions on autoimmunity will explore novel targets, CRS mitigation, immune modulation, and engineering TCEs to mimic CAR T persistence without cell therapy complexity. The program also expands beyond CD3-based formats, spotlighting new targets, immune modulators, live immune engagers, NK cell engagers, γδ T cell, and MAIT cell platforms.
Coverage will include, but is not limited to:
Next-Generation T Cell Engagers for Cancer
- Tumor targeting improvement
- Targeting intracellular antigens via pMHC, pHLA
- TCE modality engineering
- Latest engineering efforts to improve T Cell Engagers in solid tumors
- Improving safety and efficacy of TCEs through affinity tuning and optimization
- AI-powered de novo protein design for TCEs
- Engineering Conditional Activation and Tumor-Selective Engagement for TCEs
- Improving TCE function through improve synapse
- Improving delivery of TCEs
- TCR-based engagers
- Company updates
T-Cell Engagers for Autoimmune and Infectious Disease
- Latest advances, mechanisms in TCEs for autoimmune disease
- Target identification and discovery for autoimmune
- Comparisons vs. CAR-T for Autoimmune
- Designing TCEs to mimic CAR-T persistence
- Minimizing CRS toxicities
- Comparison of TCEs for oncology to autoimmune
Beyond Traditional T Cells and Cell Engagers
- Expanding beyond CD-3 based TCEs
- Gamma delta cell engagers
- MAIT Engagers
- CD8, Target Induced T-cell Activating Nanobodies (TITAN)
- NK Engagers
- Novel immune cell targeting – TriKEs, TCR-based engagers, MAIT cells
- Targeting B7H3 with immune engagers
The deadline for priority consideration is October 31, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: